Santhera Pharmaceuticals Holding AG (SPHDF)

Market Cap	265.40M +28.2%
Revenue (ttm)	61.63M -56.8%
Net Income	-82.41M
EPS	-6.81
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	909
Open	19.60
Previous Close	19.46
Day's Range	19.60 - 19.60
52-Week Range	12.28 - 22.04
Beta	-0.73
RSI	55.42
Earnings Date	Apr 28, 2026

About SPHDF

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 79
• Stock Exchange: OTCMKTS
• Ticker Symbol: SPHDF

Financial Performance

Financial numbers in CHF